Press Release
31 January 2018
Change in the Number of Shares and Votes in Immunicum
Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors (“Immunicum” or the “Company”), today announced that the number of shares and votes in Immunicum as per 31 January 2018 amounts to 50,958,531.
The number of shares and votes in Immunicum has, as a result of a rights issue of shares, increased with 24,999,990, from 25,958,541 to 50,958,531. As per 31 January 2018, there is thus 50,958,531 registered shares and votes in the Company and the share capital amounts to SEK 2,547,926.55. The quotient value per share is accordingly unchanged at SEK 0.05. Immunicum does not hold any own shares.
The information is such information that Immunicum is obliged to make public pursuant to Financial Instruments Trading Act. The information was released for public disclosure through the contact persons detailed below on 31 January 2018 at 8.00 am CET.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: +46 709 71 12 53
E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
| About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/4339bd3b-ec79-46bc-a1b6-b6802859452a
